Education
About Us
Working with TipRanks
Follow Us
Ryvu Therapeutics SA (PL:RVU)
:RVU
RVU Stock Chart & Stats
Day’s Range― - ―
52-Week Rangezł17.62 - zł54.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)26.54K
Market Cap
zł655.46M
Enterprise Valuezł657.21M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.72
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,120,148
10 Day Avg. Volume22,843
30 Day Avg. Volume26,542
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
zł25.01Price Target Upside-11.77% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
RVU FAQ
What was Ryvu Therapeutics SA’s price range in the past 12 months?
Ryvu Therapeutics SA lowest stock price was zł17.62 and its highest was zł54.20 in the past 12 months.
What is Ryvu Therapeutics SA’s market cap?
Ryvu Therapeutics SA’s market cap is zł655.46M.
When is Ryvu Therapeutics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ryvu Therapeutics SA’s earnings last quarter?
Currently, no data Available
Is Ryvu Therapeutics SA overvalued?
According to Wall Street analysts Ryvu Therapeutics SA’s price is currently Overvalued.
Does Ryvu Therapeutics SA pay dividends?
Ryvu Therapeutics SA does not currently pay dividends.
What is Ryvu Therapeutics SA’s EPS estimate?
Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ryvu Therapeutics SA have?
Ryvu Therapeutics SA has 23,120,148 shares outstanding.
What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ryvu Therapeutics SA?
Currently, no hedge funds are holding shares in PL:RVU
Company Description
Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Technical Analysis
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―
Selvita SA
―
Mabion SA
―